Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +3.37%62 Pretax Margin % is 36.25% as of Mar. 2026, which is 2998% above its 10-year median of 1.17. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 82.09% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's Pretax Margin % or its related term are showing as below:
TSE:6090'
s Pretax Margin % Range Over the Past 10 Years
Min: -42.69 Med: 1.17 Max: 21.41
Current: 15.8
TSE:6090's Pretax Margin % is ranked better than 82.09% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.31
vs TSE:6090: 15.80
Human Metabolome Technologies (TSE:6090) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Human Metabolome Technologies Pretax Margin % Related Terms
Human Metabolome Technologies Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Pretax Margin % Chart
TSE:6090 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Pretax Margin % of 36.25% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Human Metabolome Technologies and its competitors. This is 2998% above median its historical median of 1.17. According to the industry distribution chart, Human Metabolome Technologies ranks #36 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 17.9%.
Is Human Metabolome Technologies' Pretax Margin % too high?
Human Metabolome Technologies' current Pretax Margin % of 36.25% is 2998% above median its 10-year median of 1.17. Based on the distribution chart, Human Metabolome Technologies ranks #36 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #36 out of 201 companies for Pretax Margin %. This places Human Metabolome Technologies in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Pretax Margin % is 36.25%, which is 2998% above median its own 10-year median of 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current Pretax Margin % is 36.25%, which is 2998% above median its 10-year median of 1.17. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Pretax Margin % is 36.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Pretax Margin %: 36.25% (2998% above median its 10-year median of 1.17)
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
